Hospital
Prime Healthcare Services-Lehigh Acres LLC
Prime Healthcare Services-Lehigh Acres LLC was paid $5.64M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES-LEHIGH ACRES LLC
LEHIGH ACRES, FL 33936
LEHIGH ACRES, FL 33936
33aNPI1194194720assigned 09/24/2015
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$5.64M
24GClaims270,033
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,381 | $121K | |
| 2019 | 38,775 | $522K | |
| 2020 | 37,621 | $499K | |
| 2021 | 48,983 | $969K | |
| 2022 | 45,154 | $1.15M | |
| 2023 | 53,751 | $1.38M | |
| 2024incomplete | 31,368 | $1.00M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 24,006 | 22,136 | $1.89M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 15,597 | 13,960 | $1.01M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 6,031 | 5,040 | $662K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 11,226 | 9,676 | $632K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.5% | 1,985 | 1,734 | $313K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 2,720 | 2,326 | $247K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.1% | 1,113 | 982 | $118K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 7,979 | 6,937 | $94K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,568 | 1,346 | $73K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,894 | 2,913 | $66K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.1% | 316 | 296 | $60K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 623 | 547 | $59K |
111 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.0% | 5,656 | $57K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 808 | $53K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 16,609 | $46K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 84 | $22K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 436 | $20K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,801 | $18K |
| 80053 | Comprehensive metabolic panel | <1% | 15,502 | $17K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,472 | $15K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 63 | $14K |
| 81003 | <1% | 6,365 | $13K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,872 | $12K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 791 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,350 | $9K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,446 | $8K |
| 81025 | <1% | 7,681 | $7K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 123 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,912 | $5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,474 | $5K |
| 81001 | <1% | 6,411 | $5K | |
| 73630 | <1% | 309 | $5K | |
| 73562 | <1% | 287 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,393 | $4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,504 | $3K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 379 | $3K |
| 72131 | <1% | 95 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 615 | $3K |
| 73610 | <1% | 365 | $3K | |
| 87420 | <1% | 268 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,615 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 220 | $2K |
| 82962 | <1% | 1,153 | $2K | |
| 73130 | <1% | 215 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,894 | $2K |
| 84484 | <1% | 4,747 | $2K | |
| 73030 | <1% | 72 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,891 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,700 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 654 | $1K |
| G0378 | Hospital observation service, per hour | <1% | 1,246 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,213 | $1K |
| 83880 | <1% | 1,346 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,164 | $1K |
| 87040 | <1% | 1,643 | $994.47 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,336 | $930.27 |
| 84702 | <1% | 830 | $869.00 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $830.25 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,295 | $823.63 |
| 83690 | <1% | 7,111 | $782.03 | |
| 73110 | <1% | 65 | $778.92 | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $694.42 |
| 85610 | <1% | 1,950 | $602.88 | |
| 83605 | <1% | 1,120 | $578.82 | |
| 74018 | <1% | 44 | $547.31 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,460 | $528.97 |
| 85379 | <1% | 607 | $508.79 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,034 | $467.84 |
| 76801 | <1% | 152 | $427.46 | |
| 85730 | <1% | 1,405 | $361.86 | |
| 87210 | <1% | 56 | $325.18 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 654 | $300.30 |
| 96376 | <1% | 467 | $252.51 | |
| 83735 | <1% | 831 | $240.46 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 762 | $226.69 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 134 | $177.24 |
| 86900 | <1% | 246 | $174.93 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 395 | $171.97 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,365 | $149.60 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,170 | $135.30 |
| 73140 | <1% | 13 | $118.18 | |
| 82550 | <1% | 1,050 | $107.70 | |
| 94760 | <1% | 316 | $103.51 | |
| 80320 | <1% | 419 | $100.44 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 405 | $92.16 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 692 | $90.91 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 18 | $56.83 |
| 94762 | <1% | 140 | $48.31 | |
| 87070 | <1% | 1,657 | $29.44 | |
| 85014 | <1% | 513 | $25.74 | |
| 85018 | <1% | 513 | $25.74 | |
| 88312 | <1% | 304 | $7.54 | |
| 86140 | <1% | 125 | $6.61 | |
| 86901 | <1% | 230 | $4.17 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,079 | $0.08 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 54 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 281 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 77 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 76 | $0.00 |
| 80061 | Lipid panel | 0% | 104 | $0.00 |
| 90715 | 0% | 88 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 68 | $0.00 |
| 84145 | 0% | 36 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 25 | $0.00 |
| 94664 | 0% | 12 | $0.00 | |
| 71250 | 0% | 17 | $0.00 | |
| 29125 | 0% | 14 | $0.00 | |
| 72100 | 0% | 13 | $0.00 | |
| 12011 | 0% | 12 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 14 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 406 | $0.00 |
| 85027 | 0% | 15 | $0.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 276 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 136 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 56 | $0.00 |
| 80329 | 0% | 13 | $0.00 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 137 | $0.00 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 101 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 21 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 19 | $0.00 |
| J3490 | Unclassified drugs | 0% | 24 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (CHIEF COMPLIANCE COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.